CONFERENCE UPDATE: AAN 2021

9-month results from the phase 3 HELIOS-Aa study of vutrisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy

NEUROLOGY
24 Jun 2021

Get access to our exclusive articles.